SWTX:NSD-SpringWorks Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.38

Change

0.00 (0.00)%

Market Cap

USD 3.32B

Volume

0.63M

Analyst Target

USD 54.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.13 (-0.24%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

+7.30 (+0.69%)

USD 115.08B
MRNA Moderna Inc

+0.60 (+0.44%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+17.25 (+7.74%)

USD 28.20B
ARGX argenx NV ADR

+10.96 (+2.49%)

USD 26.78B
BNTX BioNTech SE

-2.23 (-2.57%)

USD 20.40B
BGNE BeiGene Ltd

-8.16 (-5.13%)

USD 17.50B
GMAB Genmab AS

-0.04 (-0.15%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.17 (-0.20%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.21 (-0.77%)

USD 15.90B

ETFs Containing SWTX

HFIN:CA Hamilton Enhanced Canadia.. 10.23 % 0.00 %

+0.03 (+-0.11%)

CAD 0.12B
FLI:CA CI U.S. & Canada Lifeco C.. 9.57 % 0.92 %

-0.05 (-0.11%)

CAD 0.09B
CEW:CA iShares Equal Weight Banc.. 9.36 % 0.60 %

-0.02 (-0.11%)

CAD 0.19B
HEF:CA Horizons Enhanced Income .. 7.65 % 0.83 %

N/A

CAD 0.16B
HMAX:CA Hamilton Canadian Financi.. 4.59 % 0.00 %

-0.02 (-0.11%)

CAD 0.78B
CDIV:CA Manulife Smart Dividend E.. 3.97 % 0.00 %

-0.02 (-0.11%)

CAD 0.49B
TQCD:CA TD Q Canadian Dividend ET.. 3.58 % 0.00 %

-0.02 (-0.11%)

CAD 0.38B
CDEF:CA Manulife Smart Defensive .. 2.52 % 0.00 %

N/A

CAD 1.25M
DXM:CA 0.00 % 0.67 %

N/A

N/A
PR:CA Lysander-Slater Preferred.. 0.00 % 1.03 %

+0.01 (+-0.11%)

CAD 0.08B
RODM Hartford Multifactor Deve.. 0.00 % 0.31 %

-0.02 (-0.11%)

USD 1.11B
TLV:CA Invesco S&P/TSX Composite.. 0.00 % 0.34 %

-0.02 (-0.11%)

CAD 0.08B
XMD:CA iShares S&P/TSX Completio.. 0.00 % 0.61 %

-0.21 (-0.11%)

CAD 0.24B
BANK:CA Evolve Canadian Banks and.. 0.00 % 0.39 %

+0.03 (+-0.11%)

CAD 0.18B
BNC:CA 0.00 % 0.68 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.11% 69% C- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.11% 69% C- 79% B-
Trailing 12 Months  
Capital Gain 52.89% 85% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.89% 85% B 89% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 24.55% 77% C+ 82% B
Dividend Return 24.55% 77% C+ 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.58% 36% F 21% F
Risk Adjusted Return 31.64% 84% B 66% D+
Market Capitalization 3.32B 94% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector